Remove tag infectious-diseases
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Figure 1 shows the targets in preclinical trials for central nervous system diseases, as sourced from GlobalData’s Drugs Database. CB1 receptors are the joint first most popular target with serotonin receptor 2A in preclinical trials for central nervous system diseases. This is closely followed by CB2 receptors in second place.

article thumbnail

‘Click’ chemistry used to tag proteins made by cancer cells 

Drug Discovery World

A new method to study the proteins released by cells, which could lead to new biomarkers for diseases including cancer, has been developed by scientists at the Francis Crick Institute and Imperial College London. . Biomarkers are valuable tools in diagnosing disease or predicting treatment outcomes, but they are challenging to find. .

Protein 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A look back at the “Joint-efforts for pathogen genomics in public health surveillance” symposium

Sciensano

The objective of this project was to implement a multidisciplinary approach and create a network of experts in order to improve the surveillance of infectious diseases with the help of cutting-edge technologies, such as high-throughput sequencing. BE READY project coordinator, Transversal activities in Applied Genomics ( TAG )).

Genome 52
article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

Tags #pctGR, @Collaboratory1 The post Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K.          Speaker Erin K. We know there is a digital gap in disadvantaged patients and elderly patients. Many patients did not answer the phone.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. However, more highly innovative/high-cost treatments, within infectious disease and neurology space, are likely to enter the market for rare disorders, increasing the number of non-oncology RSAs.

article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130
article thumbnail

Immunocore’s Kimmtrak Gets FDA Approval as First Treatment for Rare Eye Cancer and First T Cell Receptor Therapeutic

XTalks

Up to 50 percent of patients will develop metastatic disease, mainly spreading to the liver, making treatment difficult and limited. The new treatment will thus help address the unmet need for the disease. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.